A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
March 4, 2022
End Date
February 28, 2025
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
March 4, 2022
End Date
February 28, 2025